Schneider Downs Wealth Management Advisors LP Lowers Position in Johnson & Johnson (NYSE:JNJ)

Schneider Downs Wealth Management Advisors LP lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,111 shares of the company’s stock after selling 95 shares during the period. Schneider Downs Wealth Management Advisors LP’s holdings in Johnson & Johnson were worth $450,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Kovack Advisors Inc. lifted its stake in Johnson & Johnson by 0.3% during the fourth quarter. Kovack Advisors Inc. now owns 30,761 shares of the company’s stock worth $4,449,000 after purchasing an additional 88 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its holdings in shares of Johnson & Johnson by 2.1% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 950,885 shares of the company’s stock valued at $137,517,000 after buying an additional 19,500 shares in the last quarter. K.J. Harrison & Partners Inc lifted its position in Johnson & Johnson by 145.4% in the 4th quarter. K.J. Harrison & Partners Inc now owns 16,861 shares of the company’s stock worth $2,428,000 after buying an additional 9,990 shares during the last quarter. New York Life Investment Management LLC boosted its stake in Johnson & Johnson by 0.8% in the fourth quarter. New York Life Investment Management LLC now owns 328,549 shares of the company’s stock worth $47,515,000 after buying an additional 2,743 shares in the last quarter. Finally, Schnieders Capital Management LLC grew its position in Johnson & Johnson by 4.6% during the fourth quarter. Schnieders Capital Management LLC now owns 70,725 shares of the company’s stock valued at $10,228,000 after acquiring an additional 3,120 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on JNJ. Wells Fargo & Company cut their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Guggenheim boosted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Finally, Raymond James dropped their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.9 %

Shares of NYSE:JNJ opened at $165.23 on Friday. The firm has a market capitalization of $397.81 billion, a P/E ratio of 24.85, a P/E/G ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a 50 day moving average price of $150.90 and a 200-day moving average price of $156.04. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.29 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.